Autoimmune Thyroiditis in Patients with Myelopathy/Tropical Spastic Paraparesis and in HTLV-1 Carriers in Mashhad, Northeastern Iran

Morteza Taghavi, MD,* Seddigheh Fatemi, MD,** Hosein Ayatollahi,† Houshang Rafatpanah, PhD‡

*Assistant Professor of Endocrinology, Endocrine Research Center, Mashhad Medical University, mortezataghavi2003@yahoo.com and taghaviMR@mums.ac.ir
** Immunology Department, Bu Ali Research Center, Mashhad Medical University, fatemis1@mums.ac.ir
† Assistant Professor of Pathology, Mashhad Medical University, hosseinayatollahih@mums.ac.ir
‡ Immunology Department, Mashhad Medical University, Horary Research Assistant of the University of Manchester, rafatpanahh@mums.ac.ir

Contact: Dr. M. Taghavi  mortezataghavi2003@yahoo.com

Received: October 17, 2008
Accepted: October 24, 2008

Abstract. There are some reports about the association of autoimmune thyroid diseases with human T-cell leukemia virus type-I (HTLV-I) infection. The objective of this study was to estimate the seroprevalence rates of antithyroid antibodies in HTLV-I carriers and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients in Mashhad, northeastern Iran, in order to determine any association between HTLV-I infection and Hashimoto’s thyroiditis (HT).

Methods: Forty-six HTLV-I infected patients (24 patients with HAM/TSP and 22 asymptomatic carriers) and 40 HTLV-I seronegative healthy individuals were screened for the presence of thyroid autoantibodies. The diagnosis of Hashimoto’s thyroiditis was based on the presence of positive thyroid autoantibodies (antithyroid peroxidase and/or antithyroglobulin) and at least one of two additional criteria (hypothyroidism and/or goiter). Analysis of the data was done using the Fisher-Exact test and SPSS statistical software version 13.0. Any P value below 0.05 was considered statistically significant.

Results: We found thyroid autoantibodies in 14 (63.6%) of 22 asymptomatic carriers, 6 (25%) of 24 patients with HAM/TSP, and 3 (7.5%) of 40 HTLV-I seronegative healthy individuals. We found Hashimoto’s thyroiditis in 45.4% of asymptomatic carriers, 25% of HAM/TSP patients, and 5% of seronegative healthy individuals. The percentage of patients with Hashimoto’s thyroiditis was significantly higher (P<0.01) than the percentage in healthy seronegative individuals.

Conclusion: This study demonstrates a high prevalence of Hashimoto’s thyroiditis in the HAM/TSP patients and the HTLV-I carriers in Mashhad. Our findings suggest an association between HTLV-I infection and Hashimoto’s thyroiditis in our region.

Keywords. Hashimoto’s thyroiditis • HTLV-1 • Mashhad, Iran • Myelopathy/tropical spastic paraparesis • Thyroglobulin antibodies • Thyroid peroxidase antibodies

Introduction

Human T-cell leukemia virus type-I (HTLV-I) is a human retrovirus endemic in southern Japan, intertropical Africa, Melanesia, Latin America, and the Caribbean basin.[1] HTLV-I is etiologically associated with adult T-cell leukemia[2] and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).[3][4] HTLV-I may also cause some other inflammatory disorders such as uveitis,[5] chronic arthropathy,[6] pulmonary alveolitis,[7] and Sjögren’s syndrome.[8] The possible role of HTLV-I in thyroid diseases was initially raised by reports of Hashimoto’s thyroiditis in HTLV-I carriers and patients with HAM/TSP.[9][10] Graves’ disease has also been observed in HTLV-I carriers.[11][12] HTLV-I seropositivity has been a risk factor for thyroid disorders in epidemiological studies in Japan.[10][13][14][15]

The possible pathogenic role of HTLV-I in thyroid diseases is supported by many findings: HTLV-I envelope protein and tax mRNA have been detected in follicular epithelial cells of the thyroid...
tissues of a patient with Hashimoto’s thyroiditis;\textsuperscript{[16]} tax mRNA was also found in infiltrating lymphocytes in the interfollicular space;\textsuperscript{[16]} and HTLV-I proviral DNA and HTLV-I have been detected in the thyroid tissue of patients with Hashimoto’s thyroiditis and Graves’ disease.\textsuperscript{[16][17]}

The virus is also endemic in Mashhad in northeastern Iran.\textsuperscript{[18]} To our best knowledge, there has been no study in our region of the prevalence of Hashimoto’s thyroiditis among HTLV-I carriers or among HAM/TSP patients. This study had two objectives: to estimate the seroprevalence rates of antithyroid antibodies in HTLV-I carriers and HAM/TSP patients in Mashhad, and to determine whether we would find an association in the patients between Hashimoto’s thyroiditis and HTLV-I.

**Methods and Patients**

Blood samples were collected from 46 HTLV-I infected patients, 22 asymptomatic carriers (13 females and 9 males, 22-70 years old, mean age: 42.58±14.49), and 24 patients with HAM/TSP (17 females and 7 males, 17-64 years old, mean age: 38.04±11.04). Forty HTLV-I seronegative healthy individuals (26 female and 14 males, 17-65 years old, mean age: 36.84±16.32) served as normal controls. The control subjects did not have a history of thyroid or autoimmune diseases.

The diagnosis of Hashimoto’s thyroiditis was based on the presence of positive thyroid autoantibodies, thyroid peroxidase (TPO) and/or thyroglobulin (Tg), and at least one of two additional criteria: hypothyroidism and/or goiter. Antibodies to TPO and Tg were determined by RIA (Aeskalisa a-TPO, Orgentec Diagnostica, Germany). Diagnosis of HAM/TSP was based on the World Health Organization diagnosis guidelines.\textsuperscript{[19]} All patients (HTLV-I asymptomatic carriers and those with HAM/TSP) and all HTLV-I-seronegative healthy controls were Iranians living in Mashhad (HTLV-I endemic city), the northeast area of Iran.

**Statistical Analyses**

Data were descriptively expressed as mean±SD or number and percent. Statistical analysis was done by using the Fisher-Exact test with statistical software SPSS version 13.0. Any P value below 0.05 was considered statistically significant. The Endocrine Research Committee of Mashhad University reviewed all aspects of the research and approved the protocol.

**Results**

Thyroid autoantibodies were positive in 14 (63.6%) of 22 asymptomatic carriers, 6 (25%) of 24 patients with HAM/TSP, and 3 (7.5%) of 40 HTLV-I seronegative healthy individuals. In the HTLV-I carrier groups, 4 patients had subclinical hypothyroidism and 6 patients had euthyroid firm goiter. In the HAM/TSP group, 4 patients had subclinical hypothyroidism and 2 patients had euthyroid firm goiter. Seronegative healthy individuals were euthyroid and 2 of them had firm goiter. Hashimoto’s thyroiditis was found in 45.4% of asymptomatic carriers, 25% of HAM/TSP patients, and 5% of seronegative healthy individuals. Therefore, the percentage of patients with Hashimoto’s thyroiditis was significantly higher (P<0.01) than the percentage in healthy seronegative individuals.

**Discussion**

HTLV-I is a human retrovirus endemic in some areas of the world.\textsuperscript{[1]} HAM/TSP is the major syndrome caused by HTLV-I, but the virus may also cause a systemic immune-mediated inflammatory disease involving many tissues including the thyroid gland. Correlation of autoimmune thyroid diseases and HTLV-I infection were investigated recently, and the role of HTLV-I in the pathogenesis of autoimmune thyroid diseases has been demonstrated in animals and humans.\textsuperscript{[20][21][22][23][24]}

Genetic factors including human leukocyte antigen and cytotoxic T lymphocyte antigen-4 (CTLA-4) are involved in autoimmune thyroid diseases.\textsuperscript{[25][26]} However, HTLV-I infection is not associated with CTLA-4 polymorphisms in either Hashimoto’s thyroiditis patients or controls.\textsuperscript{[27]} HTLV-I infection, then, does not appear to be regulated by genetic factors, and it may cause Hashimoto’s thyroiditis as an independent, purely environmental factor.

The HTLV-I proviral load is thought to be a major determinant of HTLV-I-associated diseases. The proviral load is higher in the peripheral blood of patients with HAM/TSP than in the blood of asymptomatic carriers.\textsuperscript{[28]} It is also higher in the peripheral blood of HTLV-I-infected patients with either Hashimoto’s thyroiditis or Graves’ disease than in
HTLV-I asymtomatic carriers. Similarly, patients with HTLV-I-associated uveitis and HTLV-I-seropositive patients with arthritis or connective tissue disease have a higher proviral load than asymptomatic carriers.

Involvement of HTLV-I in the pathogenesis of autoimmune thyroid disease in Japan, where this retrovirus is endemic, has been extensively investigated. Kawai et al. reported that the prevalence of HTLV-I antibodies in Hashimoto’s thyroiditis patients, residents of the Tokushima and Kochi prefectures in Japan, was 6.3%, which was significantly higher than the expected frequency of 2.2%.

Mizokami et al. also reported that the prevalence of HTLV-I antibodies was significantly higher in patients with either antithyroid antibody-positive chronic thyroiditis (7.4%) or Graves’ disease (7%) than the expected frequency in Fukuoka prefecture, Japan. Mine et al. found that the frequency of antithyroid antibodies in blood donors with HTLV-I antibodies was significantly higher (7.9%) than that in control donors without the HTLV-I antibodies. Akamine et al. also found a high prevalence of positivity for thyroid autoantibodies in adult T-cell leukemia patients (40.4%) and HTLV-I carriers (30%).

Mashhad, a city in northeastern Iran, is also an endemic area for HTLV-I. The present study determined the seroprevalence rates of antithyroid antibodies in HTLV-I carriers and HAM/TSP patients for the first time in Iran. The study also provides data supporting the role of HTLV-I in the development of thyroid diseases in our region.

Hashimoto’s thyroiditis was found in 45.4% of asymptomatic carriers of HTLV-I and 25% of HAM/TSP patients. These percentages were significantly higher (P<0.01) than the percentage of Hashimoto’s thyroiditis in healthy seronegative individuals (5%).

Conclusion

This study demonstrates a high prevalence of positivity for antithyroid autoantibodies and Hashimoto’s thyroiditis in HAM/TSP patients and HTLV-I carriers in Mashhad. There is, then, an association between HTLV-I infection and Hashimoto’s thyroiditis in our region.

References


